Akebia Therapeutics (AKBA) Income towards Parent Company (2013 - 2026)
Akebia Therapeutics (AKBA) posted quarterly Income towards Parent Company of -$9.1 million for Q1 2026, down 248.13% year-over-year from $6.1 million in Q1 2025, and up 26.05% quarter-over-quarter from -$12.2 million in Q4 2025.
Akebia Therapeutics (AKBA) Income towards Parent Company (2013 - 2026) Analysis & Trends
Akebia Therapeutics (AKBA) has reported Income towards Parent Company for 14 consecutive years, with -$9.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Income towards Parent Company fell 248.13% year-over-year to -$9.1 million; the TTM figure through Mar 2026 stood at -$20.5 million (up 54.73% YoY), while the FY2025 annual figure was -$5.3 million, up 92.3% from the prior year.
- Income towards Parent Company improved to -$9.1 million in Q1 2026 per AKBA's latest filing, from -$12.2 million in the prior quarter.
- Across five years, Income towards Parent Company topped out at $31.4 million in Q2 2022 and bottomed at -$62.3 million in Q1 2022.
- Historically, Income towards Parent Company has averaged -$13.1 million across 5 years, with a median of -$11.2 million in 2023.
- Annual changes were most pronounced in 2022 — Income towards Parent Company surged 138.24% — and 2024, when it tumbled 3814.01%.
- Akebia Therapeutics' Income towards Parent Company stood at -$4.1 million in 2022, then soared by 114.89% to $614000.0 in 2023, then sank by 3814.01% to -$22.8 million in 2024, then jumped by 46.31% to -$12.2 million in 2025, then grew by 26.05% to -$9.1 million in 2026.
- Business Quant data shows AKBA's Income towards Parent Company at -$9.1 million in Q1 2026, -$12.2 million in Q4 2025, and $540000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - |
| 10 | Akebia Therapeutics | 249.25 Mn | 93.70 Mn | 38.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -8.91 Mn |
| Mar 31, 2026 | -9.05 Mn |
| Dec 31, 2025 | -12.24 Mn |
| Sep 30, 2025 | 540,000.00 |
| Jun 30, 2025 | 247,000.00 |
| Mar 31, 2025 | 6.11 Mn |
| Dec 31, 2024 | -22.80 Mn |
| Sep 30, 2024 | -20.04 Mn |
| Jun 30, 2024 | -8.58 Mn |
| Mar 31, 2024 | -17.99 Mn |
| Dec 31, 2023 | 614,000.00 |
| Sep 30, 2023 | -14.49 Mn |
| Jun 30, 2023 | -11.17 Mn |
| Mar 31, 2023 | -26.88 Mn |
| Dec 31, 2022 | -4.12 Mn |
| Sep 30, 2022 | -52.51 Mn |
| Jun 30, 2022 | 31.38 Mn |
| Mar 31, 2022 | -62.28 Mn |
| Dec 31, 2021 | -68.14 Mn |
| Sep 30, 2021 | -57.59 Mn |